Letter: Preliminary Observations from a Randomized,Open-Label Trial of Loperamide as Adjunctive Treatment for Social Deficits in Autism Spectrum Disorder
Restricted accessLetterFirst published online November, 2025
Letter: Preliminary Observations from a Randomized,Open-Label Trial of Loperamide as Adjunctive Treatment for Social Deficits in Autism Spectrum Disorder
BouvardMP, LeboyerM, LaunayJM, et al.Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: A double-blind, placebo-controlled study. Psychiatry Res, 1995; 58(3):191–201; doi: 10.1016/0165-1781(95)02601-R
2.
KochE, DemontisD. Drug repurposing candidates to treat core symptoms in autism spectrum disorder. Front Pharmacol, 2022; 13:995439; doi: 10.3389/fphar.2022.995439
3.
MadraM, RingelR, MargolisKG. Gastrointestinal issues and autism spectrum disorder. Child Adolesc Psychiatr Clin N Am, 2020; 29(3):501–513; doi: 10.1016/j.chc.2020.02.005
4.
NummenmaaL, TuominenL, DunbarR, et al.Social touch modulates endogenous μ opioid system activity in humans. Neuroimage, 2016; 138:242–247; doi: 10.1016/j.neuroimage.2016.05.063
5.
PellissierLP, GandíaJ, LabouteT, et al.μ opioid receptor, social behaviour and autism spectrum disorder: Reward matters. Br J Pharmacol, 2018; 175(14):2750–2769; doi: 10.1111/bph.13808
